huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Sponsor: Theriva Biologics
This PHASE1 trial investigates Pancreatic Cancer and Serous Ovarian Cancer and is currently ongoing. Theriva Biologics leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Jul 2025 — Present [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Apr 2022 — Feb 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Theriva Biologics
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .